# Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial Carcinoma

> **NCT07639983** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sheng Tai** · enrollment: 44 (estimated)

## Conditions studied

- Muscle-Invasive Bladder Cancer (MIBC)
- Urinary Bladder Cancer

## Interventions

- **DRUG:** Trastuzumab Rezetecan plus Camrelizumab

## Key facts

- **NCT ID:** NCT07639983
- **Lead sponsor:** Sheng Tai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-05
- **Primary completion:** 2028-06-05
- **Final completion:** 2028-12-31
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07639983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07639983, "Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07639983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*